FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

 OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Frankel Matthew Bejosa 2. Date of Event Requiring Statement (MM/DD/YYYY)
11/14/2022 

 3. Issuer Name and Ticker or Trading Symbol Chemomab Therapeutics Ltd. [CMMB]
(Last)        (First)        (Middle)
C/O CHEMOMAB THERAPEUTICS LTD.,, 672 PROSPECT AVE.		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Medical Officer /
(Street)
PRINCETON, NJ 08540      
(City)              (State)              (Zip)
 5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Options to Purchase American Depositary Shares (1)  (2) 11/14/2032  American Depositary Shares (1) 125000  $2.07  D   

Explanation of Responses:
(1)  Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
(2)  25% of these options will vest and become exercisable on the first anniversary of November 14, 2022, and the remaining 75% of these options will vest in equal amounts over a 36-month period commencing on November 14, 2023, subject to the Reporting Person's continued service.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Frankel Matthew Bejosa
C/O CHEMOMAB THERAPEUTICS LTD.,
672 PROSPECT AVE.
PRINCETON, NJ 08540

Chief Medical Officer

Signatures
/s/ Matthew B. Frankel 11/15/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Chemomab Therapeutics (NASDAQ:CMMB)
Historical Stock Chart
From Jan 2023 to Feb 2023 Click Here for more Chemomab Therapeutics Charts.
Chemomab Therapeutics (NASDAQ:CMMB)
Historical Stock Chart
From Feb 2022 to Feb 2023 Click Here for more Chemomab Therapeutics Charts.